ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Response Criteria"

  • Abstract Number: 1516 • ACR Convergence 2020

    The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership

    Philip Carlucci1, Kristina Deonaraine1, Andrea Fava2, Jessica Li3, David Wofsy4, Judith James5, Chaim Putterman6, Betty Diamond7, Derek Fine8, Jose Monroy-Trujillo8, Kristin Haag8, William Apruzzese9, H. Michael Belmont10, Peter Izmirly11, Sean Connery12, Fernanda Payan-Schober12, Richard Furie13, Celine Berthier14, Maria Dall'Era15, Kerry Cho16, Diane Kamen17, Kenneth Kalunian18, The Accelerating Medicines Partnership in SLE Network19, Michelle Petri20 and Jill Buyon21, 1New York University School of Medicine, New York, 2Johns Hopkins, Baltimore, 3Johns Hopkins University, Baltimore, MD, 4University of California San Francisco, San Francisco, CA, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Albert Einstein College of Medicine, Bronx, NY, 7Northwell Health, Hartford, 8Johns Hopkins University, Baltimore, 9., Boston, 10NYU School of Medicine, New York, NY, 11Department of Medicine, New York University School of Medicine, New York, NY, 12Texas Tech University Health Sciences Center, Lubbock, 13Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 14University of Michigan, Ann Arbor, 15Division of Rheumatology, University of California, San Francisco, CA, 16University of California San Francisco, San Francisco, 17Medical University of South Carolina, Charleston, SC, 18School of Health Sciences, University of California, La Jolla, 19Multiple Institutions, Multiple Cities, 20Johns Hopkins University School of Medicine, Baltimore, 21Department of Medicine, NYU School of Medicine, New York, NY

    Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…
  • Abstract Number: 1645 • ACR Convergence 2020

    Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program

    Luana Colloca1, Robert Dworkin2, John Farrar3, Leslie Tive4, Ed Whalen5, Jerry Yang4, Lars Viktrup6, Mark Brown7, Christine West7 and Kenneth Verburg8, 1University of Maryland, Baltimore, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3University of Pennsylvania, Philadelphia, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, New York, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Groton

    Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
  • Abstract Number: 1893 • ACR Convergence 2020

    Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses

    Corinne Miceli-Richard1, Denis Poddubnyy2, Atul Deodhar3, Weibin Bao4, Craig Parman5, Brian Porter6 and Effie Pournara5, 1Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 2Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Oregon Health & Science University, Portland, OR, 4Novartis Pharmaceuticals Corporation, East Hannover, 5Novartis Pharma AG, Basel, Switzerland, 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
  • Abstract Number: 2031 • ACR Convergence 2020

    Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis

    Augusta Ortolan1, Victoria Navarro-Compán2, Alexandre Sepriano3, Robert Landewé4, Désirée van der Heijde5 and Sofia Ramiro6, 1Leiden University Medical Center, Padova, Italy, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Leiden University Medical Center, Portela Loures, Portugal, 4Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 5Leiden University Medical Center, Leiden, Netherlands, 6Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies